Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNY save search
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: -9.17%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | News | $900.16 0.37% 0.32% 240K
|
Health Technology
|
| O: 0.53%
H: 1.65%
C: 0.01%
eylea fda review injection diabetic
ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M
Published: 2022-06-29 (Crawled : 12:00) - biospace.com/
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
genetic therapeutics platform
United States Human Vaccines Markets, 2018-2021 & Forecast to 2028: Approval/launches of the New Vaccines / Rising Focus on Immunization Programs / Increasing Investments and Government Support
Published: 2022-06-28 (Crawled : 21:00) - prnewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
DVAX | $11.84 0.34% 0.34% 2.6M
|
Health Technology
|
| O: 0.08%
H: 5.75%
C: 5.01%
vaccine
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
Published: 2022-06-28 (Crawled : 21:00) - globenewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
RLAY | $5.95 -0.17% -0.34% 1.1M
|
Health Technology
|
| O: -1.62%
H: 5.43%
C: 4.25%
CLLS | News | $2.64 3.53% 3.41% 24K
|
Health Technology
|
| O: -3.78%
H: 3.57%
C: 2.5%
Survey: Digital Workplaces Help Frontline Teams Look Beyond the "Big Quit"
Published: 2022-06-28 (Crawled : 15:00) - prnewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
Published: 2022-06-28 (Crawled : 13:00) - contravir.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
HEPA | $1.41 -29.85% -38.62% 320K
|
Health Technology
|
| O: -0.36%
H: 1.49%
C: -2.99%
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
Published: 2022-06-28 (Crawled : 12:00) - globenewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
GTHX | $4.1 -0.24% -0.24% 470K
|
Health Technology
|
| O: 0.0%
H: 3.18%
C: -3.18%
therapeutics
Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
Published: 2022-06-28 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
nexviadyme treatment care disease approved potential
Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
Published: 2022-06-28 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
xenpozyme treatment approved
Sanofi Enters into a Partnering Agreement with Health2Sync
Published: 2022-06-28 (Crawled : 04:00) - prnewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
agreement sanofi
MSP Recovery Commences Billing Big Pharma More Than $5.6 Billion In Billed Amounts and More Than $2.8 Billion In Paid Amounts
Published: 2022-06-28 (Crawled : 02:00) - globenewswire.com
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: 0.06%
H: 1.27%
C: -0.44%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
pharma
Sanofi: Information concerning the total number of voting rights and shares – May 2022
Published: 2022-06-27 (Crawled : 21:00) - globenewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
Cancer Immunotherapy Market Expands with Rising Adoption of Target Therapy in Cancer Treatment, States TMR Report
Published: 2022-06-27 (Crawled : 16:00) - prnewswire.com
GLAXF | News | $20.305 0.52% -14.18% 630
|
Health Technology
|
| O: 0.47%
H: 3.73%
C: 3.73%
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
GSK | News | $40.59 2.11% 0.57% 3.5M
|
Health Technology
|
| O: -0.16%
H: 0.61%
C: 0.18%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
BMY | $49.14 0.43% 0.12% 6.4M
|
Health Technology
|
| O: 0.34%
H: 1.72%
C: 0.95%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.0%
H: 2.28%
C: -2.27%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
immunotherapy report therapy cancer market treatment
COVID-19 Vaccine Leaders Make Progress on Omicron-Specific Boosters
Published: 2022-06-27 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
covid-19 vaccine
Evommune Announces Appointment of Greg Moss as Chief Corporate Strategy and Legal Officer
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Published: 2022-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
| Email alert
Add to watchlist
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
| Email alert
Add to watchlist
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
| Email alert
Add to watchlist
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
| Email alert
Add to watchlist
covid-19 vaccine response
Global Opioids Market to 2027 - Size, Share & Industry Trends Analysis Report
Published: 2022-06-24 (Crawled : 21:00) - prnewswire.com
ENDP | News | $0.2926 -9.6%
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
| Email alert
Add to watchlist
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
| Email alert
Add to watchlist
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
trends report market
Sanofi-GSK COVID-19 Vaccine Candidate Effective Against Omicron
Published: 2022-06-24 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
covid-19 candidate vaccine
Thinking about trading options or stock in Zendesk, Futu, Sanofi, Baidu, or Apple?
Published: 2022-06-24 (Crawled : 14:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Published: 2022-06-24 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
covid-19 vaccine trial results topline
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.